FDA Approved Indications for this Orphan Drug:

Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy

FDA Marketing Approval issued as of:
04/15/2016

Orphan Drug exclusivity ends on:
04/15/2023
Company Making and Marketing this drug:
Boehringer Ingelheim Pharmaceuticals, Inc.

FDA Designation Date:
8/3/15

FDA Drug Designation:
Treatment of non-small cell lung cancer with squamous histology.